GCGR agonists(Glucagon receptor agonists), GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Digestive System DisordersEndocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2Nonalcoholic SteatohepatitisObesity

Inactive Indication-

Originator Organization

Federal Biotechnology (Zhuhai Hengqin) Co., Ltd.

Active Organization

Federal Biotechnology (Zhuhai Hengqin) Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Clinical Trials associated with UBT-251

CTR20233938 / Not yet recruitingPhase 1

评估超重/肥胖患者多次皮下注射UBT251的安全性、耐受性、药代动力学、药效动力学的Ⅰ期临床试验

[Translation] A Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple subcutaneous injections of UBT251 in overweight/obese patients

主要目的：评价超重/肥胖受试者多次皮下注射UBT251的安全性和耐受性（包含局部耐受性）。次要目的：评价超重/肥胖受试者多次皮下注射UBT251注射液后的PK/PD特征；评价超重/肥胖受试者多次皮下注射UBT251注射液后的初步疗效；评价超重/肥胖受试者多次皮下注射UBT251注射液后的免疫原性。探索性目的：探索超重/肥胖受试者多次皮下注射UBT251注射液后对食欲的影响；探索超重/肥胖受试者多次皮下注射UBT251注射液对QT/QTc间期的影响。

[Translation]

Primary objective: To evaluate the safety and tolerability (including local tolerance) of multiple subcutaneous injections of UBT251 in overweight/obese subjects. Secondary objectives: To evaluate the PK/PD characteristics of overweight/obese subjects after multiple subcutaneous injections of UBT251 injection; To evaluate the preliminary efficacy of overweight/obese subjects after multiple subcutaneous injections of UBT251 injection; To evaluate the immunogenicity of overweight/obese subjects after multiple subcutaneous injections of UBT251 injection. Exploratory objectives: To explore the effect of multiple subcutaneous injections of UBT251 injection on appetite in overweight/obese subjects; To explore the effect of multiple subcutaneous injections of UBT251 injection on QT/QTc interval in overweight/obese subjects.

Start Date-

Sponsor / Collaborator

Federal Biotechnology (Zhuhai Hengqin) Co., Ltd.

CTR20234009 / Not yet recruitingPhase 1

评估成人2型糖尿病患者多次皮下注射UBT251的安全性、耐受性、药代动力学、药效动力学的Ⅰ期临床试验

[Translation] A Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple subcutaneous injections of UBT251 in adults with type 2 diabetes

主要目的：评价2型糖尿病患者多次皮下注射UBT251的安全性和耐受性（包含局部耐受性）。次要目的：评价2型糖尿病患者多次皮下注射UBT251注射液后的PK/PD特征；评价2型糖尿病患者多次皮下注射UBT251注射液后的初步疗效；评价2型糖尿病患者多次皮下注射UBT251注射液后的免疫原性。探索性目的：探索2型糖尿病患者多次皮下注射UBT251注射液对QT/QTc间期的影响。

[Translation]

Primary objective: To evaluate the safety and tolerability (including local tolerance) of multiple subcutaneous injections of UBT251 in patients with type 2 diabetes. Secondary objective: To evaluate the PK/PD characteristics of multiple subcutaneous injections of UBT251 injection in patients with type 2 diabetes; To evaluate the preliminary efficacy of multiple subcutaneous injections of UBT251 injection in patients with type 2 diabetes; To evaluate the immunogenicity of multiple subcutaneous injections of UBT251 injection in patients with type 2 diabetes. Exploratory objective: To explore the effect of multiple subcutaneous injections of UBT251 injection on the QT/QTc interval in patients with type 2 diabetes.

Start Date-

Sponsor / Collaborator

Federal Biotechnology (Zhuhai Hengqin) Co., Ltd.

CTR20232997 / RecruitingPhase 1

评估健康受试者单次皮下注射UBT251的安全性、耐受性、药代动力学、药效动力学的Ⅰ期临床试验

[Translation] A Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single subcutaneous injection of UBT251 in healthy subjects

主要目的：评价健康受试者单次皮下注射UBT251注射液的安全性和耐受性（包含局部耐受性）。次要目的：评价健康受试者单次皮下注射UBT251 注射液的药代动力学（Pharmacokinetics，PK）/药效动力学（Pharmacodynamics，PD）特征；评价健康受试者单次皮下注射UBT251注射液的免疫原性特征。

[Translation]

Primary objective: To evaluate the safety and tolerability (including local tolerance) of a single subcutaneous injection of UBT251 injection in healthy subjects. Secondary objective: To evaluate the pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of a single subcutaneous injection of UBT251 injection in healthy subjects; To evaluate the immunogenicity characteristics of a single subcutaneous injection of UBT251 injection in healthy subjects.

Start Date10 Oct 2023

Sponsor / Collaborator

Federal Biotechnology (Zhuhai Hengqin) Co., Ltd.

100 Clinical Results associated with UBT-251

100 Translational Medicine associated with UBT-251

100 Patents (Medical) associated with UBT-251

100 Deals associated with UBT-251

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 1	CN	Federal Biotechnology (Zhuhai Hengqin) Co., Ltd.	10 Oct 2023
Nonalcoholic Steatohepatitis	Phase 1	CN	Federal Biotechnology (Zhuhai Hengqin) Co., Ltd.	10 Oct 2023
Obesity	Phase 1	CN	Federal Biotechnology (Zhuhai Hengqin) Co., Ltd.	10 Oct 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

UBT-251

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation